Praxis Precision Medicines Inc (PRAX) FinancialsPRAXPraxis Precision Medicines Inc

Evaluating the bottom line, Praxis Precision Medicines, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -38.86%, provide a clear picture of how effectively PRAX converts its operational activities into shareholder value.

In the context of the broader market, PRAX competes directly with industry leaders such as IONS and ALKS. With a market capitalization of $8.13B, it holds a leading position in the sector. When comparing efficiency, PRAX's gross margin of N/A stands against IONS's 98.98% and ALKS's 75.67%. Such benchmarking helps identify whether Praxis Precision Medicines, Inc. is trading at a premium or discount relative to its financial performance.

Praxis has reported substantial net losses, with expected net income of -92561000 USD in Q1 2026 and a forward P/E ratio of 0, indicating no earnings expected in the near term.